We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

9 hedge funds and large institutions have $174K invested in Northwest Biotherapeutics, Inc. Common stock in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more funds holding

Funds holding: 8 → 9 (+1)

8% more capital invested

Capital invested by funds: $160K → $174K (+$13.4K)

Holders
9
Holders Change
+1
Holders Change %
+12.5%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EFG
Ethos Financial Group
Pennsylvania
+$6.51K
2
MSAM
Moloney Securities Asset Management
Missouri
+$345

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
MSAM
1
Moloney Securities Asset Management
Missouri
$120K +$345 +1,440 +0.3%
VWA
2
VSM Wealth Advisory
Maryland
$15.7K – – –
OCG
3
Opus Capital Group
Ohio
$14K – – –
EFG
4
Ethos Financial Group
Pennsylvania
$12.6K +$6.51K +25,350 +107%
WJWM
5
Williams Jones Wealth Management
New York
$6.48K – – –
KA
6
KLCM Advisors
Wisconsin
$2.4K – – –
AMG
7
Advisors Management Group
Wisconsin
$2K – – –

NWBO Hedge Fund Activity: Q2 2025 in Review

9 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2025, worth a combined $174K — up 8.3% from $160K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new NWBO positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Ethos Financial Group, adding an estimated $6.51K.

  • 9 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2025, up from 8 in Q1 2025.
  • Funds reported $174K of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2025, up 8.3% quarter-over-quarter.
  • 1 fund opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2025 and 0 closed out, a net change of +1 holder.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2025 was Ethos Financial Group, an estimated $6.51K added.

Based on aggregated 13F filings for Q2 2025.